Support

Alivus Life Sciences Ltd IPO Synopsis

An Initial Public Offering is an opportunity for investors to take part in the growth of a company. It is always better to be in the first batch of investors. The shares offered by the company get listed on the stock exchanges and can be bought and sold by investors.

Login to APPLY

Alivus Life Sciences Ltd IPO

Registered Office: Plot No. 170-172 Chandramouli,Industrial Est.Mohol Bazarpeth , Solapur - 413213 , Maharashtra , India.
Phone : 91-2189-234456/234246   Fax:
Email :  complianceofficer@glenmarklifesciences.com  
Website :  www.glenmarklifesciences.com
Initial public offer of 21,022,222 equity shares of face value of (Rs)2 each ("equity shares") of Glenmark Life Sciences Limited ("Company" or "Issuer") for cash at a price of (Rs)720 per equity share (including a share premium of (Rs)718 per equity share) aggregating to (Rs)1513.60 crores (the "offer") comprising a fresh issue of 14,722,222 equity shares aggregating to (Rs)1060 crores (the "fresh issue") and an offer for sale of up to 6,300,000 equity shares by Glenmark Pharmaceuticals Limited ("Promoter Selling Shareholder") and such equity shares, The "offered shares") aggregating to (Rs)453.60 crores (The "offer for sale"). The offer shall constitute 17.16% of the post-offer paid-up equity share capital of the company. The face value of equity shares is (Rs)2 each. Offer Price : (Rs)720 per Equity Share of face value of (Rs)2 each. Anchor Investor offer price: (Rs)720 per Equity share. The Offer Price is 360 times the face value.

Issue Money Payable On
Opens On Closes On Application Allotment
27-Jul-21 29-Jul-21 (Rs)720.00-0.00 (Rs)0.00-0.00
Minimum Application for shares in Nos :20  Further Multiples of :20

  (Rs Cr) Lead Managers to the Issue
Project Cost 1060.00
BOB Capital Markets Ltd
Project Financed through Current Offer 1513.60  
Post Issue Equity Share Capital 24.51  
Issue Price (Rs)720.00  
 
Projects
Payment of outstanding purchase consideration to the promoter for the spin-off of the API business from the promoter into the company pursuant to the Business Purchase agreementGeneral corporate purposes
Funding capital expenditure requirements
Promoted By
Glenmark Pharmaceuticals Ltd  
Listing At
BSE 
NSE 
Registrar to the Issue
KFin Techologies Ltd